Workflow
思宇MedTech
icon
Search documents
报名倒计时!首届全球心血管大会
思宇MedTech· 2025-05-10 02:26
心未来 为促进心血管医工合作、技术创新,思宇MedTech、心未来将于 2025年5月15日(星期四) ,在北京中关村展示中心举办 首届全球心血管大会 (GCC2025)暨创新颁奖典礼 。 报名从速,锁定参会席位~ (注:参会免费! 前期填表的已拉群;没有入群的,请通过工作人员好友申请,方便后续发地址、会刊等。) 2025心血管创新白皮书目录 四、会议规模: 现场参会嘉宾500人 五、大会议程(暂定,持续更新中): 首届全球心血管大会 Global Cardiovascular Conference 2025 暨2025行业颁奖典礼 一、活动时间: 2025年5月15日 星期四 9:00-12:30 (下午为政府闭门对接会,请希望参会的CEO私信 联系赵清微信号qingzhao2017 ) 二、活动地点: 中关村展示中心会议中心(新建宫门路2号) 三、主办单位: 心未来、思宇MedTech; 协办单位:中关村联新生物医药产业联盟,M edtec医疗器械设计与制造技术展览会 支持单位:启迪之星,中关村科学城CGT产业孵化中心 | | | 于洋,北京安贞医院科技处处长、成果转化办公室副主任; 心脏外科主任医师、教 ...
路演报名:医疗科技项目融资路演第41期
思宇MedTech· 2025-05-10 02:26
主办方: 思宇MedTech、中关村联新生物医药产业联盟 协办方: 北京通和立泰生物科技有限公司、中关村医疗器械园有限公司 路演时间 : 2025年5月29日星期四下午14:00 路演形式: 线上,腾讯会议;现场路演 地点: 中关村医疗器械园 项目报名方式: 复制此链接到浏览器中填写。 https://docs.qq.com/form/page/DUFBzS2xteFh1ZUph 点击文末 "阅读原文" 填写报名表,或者复制链接到浏览器中填写。 或扫描二维码进行填写 (注:以上是CEO报名表。投资人报名通知会在路演前五天发出。) 思宇MedTech组织的项目路演特色: 1. 创始人为研发或医生背景,良好的教育和职业履历。 2. 参与的投资人是经过审核的、有相关投资案例的机构。 3. 项目可直接对接投资人,简单高效。 1 哪些项目可以报名? 路演后续如何推进? 1. 融资阶段:天使轮~C轮之间均可。 路演时,请项目方直接将联系方式留在PPT上,等待投资机构主动联系;我们也会帮投资人对接项目 CEO;或者把微信号发到投资人群中。 哪些投资人会参加路演? 4 项目报名方式 2 2. 优先医院医生的科技成果转化项目。 ...
报名!顶层认知+落地方法论,上交大医健未来领军人才班
思宇MedTech· 2025-05-10 02:26
Core Viewpoint - The article emphasizes the importance of a comprehensive understanding of the medical and health ecosystem, highlighting the need for entrepreneurs to develop strategic thinking and innovative capabilities to navigate the complexities of the industry [4][11]. Group 1: Program Overview - The program aims to cultivate leadership talents in the medical and health sector by providing a robust academic support system, innovative platforms, and clinical transformation resources [6][9]. - It features a unique value engine methodology that focuses on collaborative efforts between academia and industry to enhance strategic vision and innovation capabilities [7][8]. Group 2: Course Benefits - The curriculum addresses trends, challenges, and innovations in the medical industry, helping participants understand the development trajectory and future direction of the sector [11]. - It explores how to create a sustainable growth strategy for enterprises in uncertain environments, emphasizing the importance of opportunity identification and risk avoidance [12][13]. Group 3: Curriculum Modules - The program includes modules on entrepreneurial thinking in uncertain times, macroeconomic growth logic, and strategic diagnosis for effective execution [16]. - It covers topics such as value discovery, business model design, and investment decision-making in the healthcare sector [17]. Group 4: Networking and Resources - The program facilitates connections with top-tier resources, including visits to leading hospitals and enterprises in the medical field, fostering collaboration and innovation [21]. - It offers opportunities for global learning experiences, including visits to renowned institutions in the United States and Europe [22].
报名!医工交叉实战工作坊 | 上海
思宇MedTech· 2025-05-09 10:43
Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1][4]. Training Highlights - The workshop aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [4]. - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on efficient transformation [5]. - The program includes insights into the medical device industry trends, practical empowerment through design thinking and interdisciplinary collaboration, and opportunities for project exposure to potential investors [5]. Target Audience - The workshop is suitable for various professionals, including doctors from different departments, engineering personnel from research institutions, industry and investment practitioners, and entrepreneurs interested in medical device innovation [5]. Course Structure - The two-day intensive training covers medical innovation and technology layout, innovation practice, team exercises, and discussions on the key paths from concept to market [6][10]. - The first day includes sessions on medical innovation, technology layout, and practical exercises to foster collaboration among participants [6][8]. - The second day focuses on innovation industrialization and funding pathways, including discussions on financing, government support policies, and investment opportunities [12][15]. Expert Faculty - The workshop features a team of distinguished experts from Shanghai Jiao Tong University, including leaders in biomedical engineering and medical technology innovation, who will share their insights and experiences [13][16]. Registration Information - The workshop is scheduled for June 21-22, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per person, covering course materials and refreshments [9][18].
奖项申报通知 | 第二届全球医疗科技大会
思宇MedTech· 2025-05-09 10:43
Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end intelligent diagnostic equipment, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1] Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical application [1][4] - The first conference, Global MedTech Conference 2024, was organized by Siyu [2] Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Clinical Application Award [3][7] - The awards aim to honor innovative products or platform technologies with originality, advancement, and potential for large-scale industrialization [6] Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5] - Other topics will cover AI-assisted diagnosis, digital therapy breakthroughs, and insights into technology directions and enterprise profiles that attract domestic and foreign capital [5] Group 4: Participation and Submission Process - Companies interested in participating in the awards must fill out a designated form and submit relevant documents by May 31, 2025 [9][10] - The evaluation phase will occur from June 1 to June 15, 2025, with results announced between June 16 and June 22, 2025 [10]
评奖报名!首届全球医美科技大会暨行业颁奖典礼
思宇MedTech· 2025-05-09 10:43
近年来,医疗美容行业迅猛发展,材料科学、生物技术、激光光电、再生医学等前沿科技正在重塑医美产 业生态。为促进全球医美科技领域的交流合作,加速医工交叉创新成果转化,推动行业高质量发展,思宇 将 于 2025 年 6 月 12 日 在 北 京 中 关 村 展 示 中 心 举 办 " 首 届 全 球 医 美 科 技 大 会 " ( Global Aesthetic Technology Conference 2025) 。 大会将汇聚来自全球医疗美容产业的临床专家、顶尖科学家、科技创新者、投资机构与政府监管部门,共 同探讨医美科技前沿动态、创新技术产业化路径、政策监管趋势以及市场新机遇。 举办地点: 北京中关村展示中心 会议规模: 现场500人 参会对象: 涵盖政府、医院、医美上下游企业、投资机构等综合性高知人士 大会议程要点(拟) 为表彰医疗美容科技领域内的卓越贡献,思宇MedTech及旗下专业媒体将组织评选2025全球医美科技创 新系列奖项,并于大会开幕式现场颁发。 一、奖项名称及评选规则 2025全球医美科技创新奖 2025 Global Aesthetic Technology Innovation Awa ...
美敦力老将加入创新械企,他看中了什么?
思宇MedTech· 2025-05-09 08:06
报名:首届全球心血管大会 | 最新议程 合作伙伴征集:2025全球手术机器人大会 2025年5月9日,创新心血管医疗器械公司CorFlow Therapeutics宣布,任命Chris O'Connell为董事会主席,接替Rick Geoffrion的职务。 这一人事变动并不简单。Chris O'Connell的职业履历高度浓缩了 全球医疗器械"头部经验" :他在 美敦力工作了21年 ,先后主导过心血管、糖尿病及修复治疗事 业部,是当年美敦力扩张黄金期的执行委员会核心成员;此后,又担任Waters Corporation总裁兼CEO五年,带领公司实现营收与市值的双重增长。 过去几年,Chris以独立董事身份出现在多家医疗器械与生命科学公司董事会中。但这一次,他选择在CorFlow"上桌",担任董事会主席。 从一家全球巨头到一家术式仍在试验阶段的公司,这不是轻易的决定。 CorFlow究竟做了什么,让这样一位业内老将愿意下注? # CoFI:从"术中看不见的MVO",到实时诊断+局部治疗 CorFlow的核心平台为 Controlled Flow Infusion(CoFI)系统 ,聚焦于 微血管阻塞(MVO) ...
43亿!骨科巨头公布最新财报
思宇MedTech· 2025-05-09 08:06
报名:首届全球心血管大会 | 最新议程 合作伙伴征集:2025全球手术机器人大会 2025年5月8日,全球骨科领先企业Globus Medical(纽约证券交易所代码:GMED)公布了其截至2025年3月31日季度的财务业绩,第一季度全 球净销售额为 5.981亿美元(约合 43亿人民币) ,同比下降1.4%。 # 财报数据 公司总裁兼首席执行官 Dan Scavilla 表示, "第一季度的业绩受到多重因素的影响,包括 技术交易关闭放缓、供应链中断,以及国际经销商订单波动 。然 而,核心美国脊柱业务表现出色,部分抵消了这些不利因素。我们将继续加大投资力度,致力于提供创新且临床先进的产品和解决方案。" 首席运营官兼首席财务官 Keith Pfeil 表示, "本季度公司 成功恢复了无债务状态,偿还了因收购NuVasive而承担的剩余4.5亿美元债务。 同时,第一季度 自由现金流创下纪录。在扩大内部制造规模的过程中,我们继续 在机器、设备和器械套装方面进行投资 。" # 211亿大手笔收购的背后 2023年2月,Globus Medical与NuVasive宣布,以31亿美元(约合人民币211亿元)达成最终收购 ...
进入创新通道!又一款体外诊断产品
思宇MedTech· 2025-05-09 08:06
Group 1: Tuberculosis Overview - Tuberculosis (TB) is a serious infectious disease caused by Mycobacterium tuberculosis, posing a significant global public health threat [3] - In 2021, China accounted for 7.4% of the global TB incidence, ranking third worldwide, with a treatment success rate for drug-resistant TB at only 53% compared to 95% for regular TB [3][6] - In 2021, there were 1.6 million deaths from TB globally, making it the 13th leading cause of death, just after COVID-19 [6] Group 2: Drug-Resistant Tuberculosis - The emergence of drug-resistant TB (MDR-TB and XDR-TB) complicates TB control efforts, leading to increased treatment difficulty, lower cure rates, and higher mortality [5] - In 2021, there were 450,000 new cases of MDR/RR-TB, with a treatment success rate of only 60% [6] Group 3: Limitations of Traditional Testing Methods - Traditional drug resistance testing methods are time-consuming, often taking weeks to months, and have low sensitivity and specificity [7] - Rapid molecular testing can provide quicker results but is limited in identifying a comprehensive range of drug resistance mutations [7] Group 4: Reversible Terminator Sequencing (RTS) - RTS is a high-precision DNA sequencing technology that allows for single-base resolution sequencing, significantly improving accuracy and sensitivity [8] - The technology is suitable for rapid diagnosis and clinical applications, completing the sequencing process in a short time [8] Group 5: Targeted Next-Generation Sequencing (tNGS) - tNGS integrates multiplex PCR/hybrid capture with next-generation sequencing, providing precise analysis of specific gene regions and comprehensive drug resistance information [9] - The tNGS method can analyze multiple antibiotic resistance genes simultaneously, aiding in early diagnosis and personalized treatment strategies [16] Group 6: Gold Standard Testing Kit - The Mycobacterium tuberculosis complex drug resistance gene mutation detection kit (RTS) combines tNGS with multiplex PCR, covering 13 resistance genes and over 200 mutation sites [13] - The kit can provide results in under 12 hours, with a sequencing run time of less than 5 hours, allowing for rapid detection of drug resistance [13] Group 7: Clinical Data and Performance - Clinical studies show that tNGS has an average consistency of 95.10% with phenotypic antimicrobial susceptibility testing (AST) and 97.05% with whole genome sequencing (WGS) [18] - In 158 bronchoalveolar lavage fluid samples, tNGS had a positivity rate of 87.95%, outperforming Xpert MTB/RIF [18] Group 8: Competitor Products - Cepheid's Xpert MTB/RIF offers rapid detection of Mycobacterium tuberculosis and rifampicin resistance with a sensitivity of 133 bacteria/mL, providing results in 2 hours [19] - Hain Lifescience's GenoType MTBDRplus uses linear probe hybridization for detecting TB and drug resistance, with a 48-hour turnaround time [20] - Becton Dickinson's BD MAX MDR-TB detects multiple drug resistance genes with high sensitivity and specificity, providing results in 2 hours [21] Group 9: Company Profile - Guangzhou Jinquirui Biotechnology Co., Ltd. focuses on the development, production, and sales of precision medical in vitro diagnostic products, established in 2016 [22] - The company has developed various technologies, including multiplex PCR and tNGS, and has received multiple core technology patents [24] - Jinquirui is one of the few companies in China providing a comprehensive solution for tumor and infection diagnostics, including gene sequencing instruments and clinical applications [24]
3.32亿元!心脉医疗发布最新季报
思宇MedTech· 2025-05-09 08:06
Core Viewpoint - Shanghai MicroPort Cardiac Interventional Medical Technology (Group) Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating potential challenges in the company's financial performance and operational efficiency [2][6]. Financial Performance - The company's revenue for Q1 2025 was 332 million yuan, a year-on-year decrease of 7.23% [6]. - The net profit attributable to shareholders was 130 million yuan, down 29.66% year-on-year; the net profit excluding non-recurring items was 122 million yuan, a decline of 31.27% [6]. - Gross margin was 69.61%, down 6.90% year-on-year, while net margin was 38.53%, a decrease of 12.54% [6]. - Basic earnings per share were 1.05 yuan [6]. Expense Analysis - Total operating expenses (selling, administrative, and financial expenses) amounted to 63.01 million yuan, increasing from 9.72% to 18.97% of total revenue, a growth of 95.05% [7]. - Selling expenses rose by 68.09%, administrative expenses increased by 60.62%, while R&D expenses decreased by 31.26% and financial expenses grew by 56.24% [7]. Asset Status - As of the end of the reporting period, the company's cash and cash equivalents were 1.086 billion yuan, a decrease of 26.32% year-on-year [8]. - Accounts receivable stood at 355 million yuan, an increase of 83.78% year-on-year [8]. - Interest-bearing liabilities reached 152 million yuan, a significant increase of 1217.07% year-on-year [8]. Business Development - The company has made progress in the active artery intervention field, with several products receiving regulatory approvals and entering clinical trials [11][16]. - Key products include the Cratos® branched aortic stent system and Hector® thoracic aortic multi-branch stent system, both of which have received domestic approval [11]. - The company has subsidiaries focused on various interventional fields, enhancing its market presence and product offerings [15].